US startup Helex raises $3.5M to advance preclinical kidney program

Helex, a therapeutics startup based in the US and India, has closed a US$3.5 million seed round led by pi Ventures, with participation from Bluehill Capital, SOSV, and other investors.

The company, headquartered in New York and focused on developing targeted medicines for genetic kidney diseases, has now raised over US$6 million in total funding.

Helex plans to use the new capital to advance the preclinical development of its lead program for autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder affecting over 12 million people worldwide.

The startup is also working on a kidney-targeted lipid nanoparticle (LNP) delivery system and a 3D genome-based drug design platform.

Helex was founded in 2021 and operates out of Hyderabad and Cambridge.

The company’s approach involves non-viral gene editing therapies aimed at delivering genetic treatments directly to kidney cells.

🔗 Source: Helex

🧠 Food for thought

Implications, context, and why it matters.

Helex kidney LNP needs outside proof

Helex says its lipid nanoparticles reach the kidney by escaping glomerular filtration 1. Helex tunes size, charge, and PEGylation (adding polyethylene glycol (PEG) chains to change behavior in the body) to hit cells 1. No peer-reviewed papers, preprints, or independent posters back biodistribution claims.
The company adds its approach has lower immunogenicity (less likely to trigger an immune response) and avoids insertional mutagenesis risk (unintended DNA integration that disrupts genes) vs viral vectors (engineered viruses used for delivery) 1.
Nephrogen claims a delivery mechanism 100 times more efficient than FDA-approved vehicles for kidney gene therapy 2, yet no head-to-head or third-party tests size Helex’s edge.

Vendors can serve kidney gene therapy

Judo Bio is developing kidney-delivered oligonucleotide therapies (short DNA or RNA drugs) with its STRIKE platform (the company’s targeting and delivery system) for use in polycystic kidney disease 3. Chiesi set up to $115 million in upfront plus near-term payments for Arbor, a gene editing biotech, and its ABO-101 treatment 4.
Contract research organizations offering biodistribution imaging, kidney toxicology, and LNP characterization can move early. Map 2025 programs across Helex and Nephrogen 2. Cover Judo Bio 3 plus Arbor 4. Then pitch renal targeting packages before requests for proposals.
Suppliers of ionizable lipids (charge-switching lipids used to form LNPs), PEGylation reagents, and guide RNA (the RNA that directs gene editors to the target DNA) synthesis should prioritize outreach since kidney delivery needs differ from liver-targeted LNP work dominating development.